干细胞移植改善心力衰竭时的心脏功能评价

Stem cell transplantation for improving cardiac failure:An evaluation of cardiac function

心力衰竭是各种心血管疾病的终末阶段,由于大多数心肌细胞和神经细胞一样,属于永久性细胞,其数量是有限的。治疗方法如药物治疗、外科治疗和介人治疗得到了改进,但因都不能使心肌数量增加,只在一定程度上缓解了心力衰竭的发生或症状,不能达到令人满意的程度,晚期患者常需要进行心脏移植,而供体难以获得、免疫排斥反应、费用的昂贵及手术的高风险使心脏移植治疗受到很大的限制。要想从根本上解决问题就必须使心肌细胞数量增加,血供增加。随着分子生物学的飞速发展,基因或骨髓间充质干细胞可作为一种药物直接或间接对损伤的病变进行补充或修复。细胞重建和功能恢复的干细胞移植疗法成为有应用前景的研究热点。

Cardiac failure is an end phase of varied cardiovascular diseases. Most cardiomyocytes as neural cells belong to permanent cells, with limited quantity. Therapeutic methods have been improved such as drug therapy, surgical therapy and intervention therapy. These methods cannot increase the number of cardiomyocytes, only relieve the occurrence or symptom of cardiac failure to some extents, which is not satisfactory. Patients in the advanced stage should receive heart transplantation. However the heart transplantation has been greatly limited, due to the donor is hard to obtain, immunological rejection, high cost and high risk. To work out this solution, we should increase cardiomyocyte number and blood supply. With the rapid development of molecular biology, gene or bone marrow mesenchymal stem cells can be used as a drug to supply or repair injured lesion directly or indirectly. Stem cell transplantation for cell reestablishment and functional recovery can be a research hotspot with a good application perspective.